These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 30529386)
1. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis. Fan Y; Bazai SK; Daian F; Arechederra M; Richelme S; Temiz NA; Yim A; Habermann BH; Dono R; Largaespada DA; Maina F J Hepatol; 2019 Mar; 70(3):470-482. PubMed ID: 30529386 [TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349 [TBL] [Abstract][Full Text] [Related]
3. Tschida BR; Temiz NA; Kuka TP; Lee LA; Riordan JD; Tierrablanca CA; Hullsiek R; Wagner S; Hudson WA; Linden MA; Amin K; Beckmann PJ; Heuer RA; Sarver AL; Yang JD; Roberts LR; Nadeau JH; Dupuy AJ; Keng VW; Largaespada DA Cancer Res; 2017 Dec; 77(23):6576-6588. PubMed ID: 28993411 [TBL] [Abstract][Full Text] [Related]
4. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. Arechederra M; Bazai SK; Abdouni A; Sequera C; Mead TJ; Richelme S; Daian F; Audebert S; Dono R; Lozano A; Gregoire D; Hibner U; Allende DS; Apte SS; Maina F J Hepatol; 2021 Apr; 74(4):893-906. PubMed ID: 33197513 [TBL] [Abstract][Full Text] [Related]
5. A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases. Fan Y; Arechederra M; Richelme S; Daian F; Novello C; Calderaro J; Di Tommaso L; Morcrette G; Rebouissou S; Donadon M; Morenghi E; Zucman-Rossi J; Roncalli M; Dono R; Maina F Hepatology; 2017 Nov; 66(5):1644-1661. PubMed ID: 28586114 [TBL] [Abstract][Full Text] [Related]
6. Two-Step Forward Genetic Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma. Kodama T; Bard-Chapeau EA; Newberg JY; Kodama M; Rangel R; Yoshihara K; Ward JM; Jenkins NA; Copeland NG Gastroenterology; 2016 Aug; 151(2):324-337.e12. PubMed ID: 27178121 [TBL] [Abstract][Full Text] [Related]
7. Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma in mice. Riordan JD; Feddersen CR; Tschida BR; Beckmann PJ; Keng VW; Linden MA; Amin K; Stipp CS; Largaespada DA; Dupuy AJ Hepatology; 2018 Mar; 67(3):924-939. PubMed ID: 28961327 [TBL] [Abstract][Full Text] [Related]
8. Sleeping Beauty insertional mutagenesis screen identifies the pro-metastatic roles of CNPY2 and ACTN2 in hepatocellular carcinoma tumor progression. Lo LH; Lam CY; To JC; Chiu CH; Keng VW Biochem Biophys Res Commun; 2021 Feb; 541():70-77. PubMed ID: 33482578 [TBL] [Abstract][Full Text] [Related]
9. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Matalkah F; Martin E; Zhao H; Agazie YM Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598 [TBL] [Abstract][Full Text] [Related]
14. HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-Mediated Anti-Tumorigenesis and Phagocytosis of Hepatocellular Carcinoma. Yang HD; Kim HS; Kim SY; Na MJ; Yang G; Eun JW; Wang HJ; Cheong JY; Park WS; Nam SW Hepatology; 2019 Oct; 70(4):1262-1279. PubMed ID: 30991448 [TBL] [Abstract][Full Text] [Related]
16. The DNA methylation profile of liver tumors in C3H mice and identification of differentially methylated regions involved in the regulation of tumorigenic genes. Matsushita J; Okamura K; Nakabayashi K; Suzuki T; Horibe Y; Kawai T; Sakurai T; Yamashita S; Higami Y; Ichihara G; Hata K; Nohara K BMC Cancer; 2018 Mar; 18(1):317. PubMed ID: 29566670 [TBL] [Abstract][Full Text] [Related]
17. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours. Nwosu ZC; Battello N; Rothley M; Piorońska W; Sitek B; Ebert MP; Hofmann U; Sleeman J; Wölfl S; Meyer C; Megger DA; Dooley S J Exp Clin Cancer Res; 2018 Sep; 37(1):211. PubMed ID: 30176945 [TBL] [Abstract][Full Text] [Related]
18. Mediator subunit 23 overexpression as a novel target for suppressing proliferation and tumorigenesis in hepatocellular carcinoma. Guo Y; Wang J; Li H; Liu W; Chen D; Zhao K; Liang X; Zhang Q; Yang Y; Chen G J Gastroenterol Hepatol; 2015 Jun; 30(6):1094-103. PubMed ID: 25684393 [TBL] [Abstract][Full Text] [Related]
19. A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. O'Donnell KA; Keng VW; York B; Reineke EL; Seo D; Fan D; Silverstein KA; Schrum CT; Xie WR; Mularoni L; Wheelan SJ; Torbenson MS; O'Malley BW; Largaespada DA; Boeke JD Proc Natl Acad Sci U S A; 2012 May; 109(21):E1377-86. PubMed ID: 22556267 [TBL] [Abstract][Full Text] [Related]
20. Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma. Chiu AP; Tschida BR; Lo LH; Moriarity BS; Rowlands DK; Largaespada DA; Keng VW World J Gastroenterol; 2015 Nov; 21(42):12157-70. PubMed ID: 26576100 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]